Study of Anti-HIV Therapy Intensification
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Lopinavir, OspA Protein, HIV-1, HIV Protease Inhibitors, CD4 Lymphocyte Count, Ritonavir, Haemophilus Vaccines, HAART, Pneumococcal Vaccines, tenofovir disoproxil
Eligibility Criteria
Inclusion Criteria Patients may be eligible for this study if they: Have completed ACTG 375 within 2 weeks of finishing Week 230. Have a viral load less than 400 copies/ml within 90 days prior to study entry. Agree not to become pregnant or to impregnate during the study. The female patient/male partner must use acceptable methods of contraception while receiving study drugs and for 1 month after stopping the drugs. Women and men who cannot have children are eligible without requiring the use of contraception, but they must provide acceptable documentation of menopause, sterilization, or lack of sperm cells. Exclusion Criteria Patients may not be eligible for this study if they: Need to use certain drugs within 30 days of study entry. Have taken any immunomodulatory therapies within 30 days prior to study entry unless approved by the protocol chairs. Have a history of serious kidney problems. Are allergic or sensitive to the study drugs. Are pregnant or breast-feeding. Have an alcohol or drug dependency that, in the opinion of the investigator, would interfere with the study.
Sites / Locations
- University of Colorado Hospital CRS
- Rush Univ. Med. Ctr. ACTG CRS
- Case CRS